In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Axovant raises $25mm in PIPE to support licensing of OXB102 from Oxford BioMedica

Executive Summary

Axovant Sciences Ltd. grossed $25mm through the private sale of 14.3mm common shares at $1.75 (a 17% premium) to parent Roivant Sciences. The company will use the proceeds to support development of OXB102, which Axovant in-licensed from Oxford BioMedica in a concurrent agreement worth up to $842.5mm. The preclinical gene therapy candidate, which Axovant renamed AXO-Lenti-PD, is an in vivo lentiviral vector designed to increase dopamine production and reduce motor fluctuations in Parkinson’s disease patients.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Private Investment in Public Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register